[{"address1": "1359 Broadway", "address2": "Suite 1710", "city": "New York", "state": "NY", "zip": "10018", "country": "United States", "phone": "212 433 3791", "website": "https://zentalis.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its product candidates include ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, for the treatment of advanced solid tumors and hematological malignancies. It is in a Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; a Phase 2 clinical trial in Cyclin E1-driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; a Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; a Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, peritoneal, or fallopian tube cancer; a Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; a Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and a Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's product pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; and Dana-Farber. The company was incorporated in 2014 and is headquartered in New York, New York.", "fullTimeEmployees": 166, "companyOfficers": [{"maxAge": 1, "name": "Ms. Andrea  Paul J.D.", "age": 42, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 682466, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Julie M. Eastland M.B.A.", "age": 60, "title": "CEO, President & Director", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Vincent A. Vultaggio", "age": 40, "title": "SVP of Finance & Principal Accounting Officer", "yearBorn": 1984, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark  Lackner Ph.D.", "age": 56, "title": "Chief Scientific Officer", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Wendy  Chang", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kimberly  Freeman", "title": "Chief Strategy Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ingmar  Bruns M.D., Ph.D.", "age": 48, "title": "Chief Medical Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Haibo  Wang", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.26, "open": 1.25, "dayLow": 1.23, "dayHigh": 1.34, "regularMarketPreviousClose": 1.26, "regularMarketOpen": 1.25, "regularMarketDayLow": 1.23, "regularMarketDayHigh": 1.34, "payoutRatio": 0.0, "beta": 1.801, "forwardPE": -0.36134455, "volume": 889002, "regularMarketVolume": 889002, "averageVolume": 1567500, "averageVolume10days": 919570, "averageDailyVolume10Day": 919570, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 92636840, "fiftyTwoWeekLow": 1.01, "fiftyTwoWeekHigh": 13.46, "priceToSalesTrailing12Months": 1.3739243, "fiftyDayAverage": 1.8041, "twoHundredDayAverage": 2.91745, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -235798160, "profitMargins": -2.45961, "floatShares": 45013608, "sharesOutstanding": 71811504, "sharesShort": 4769777, "sharesShortPriorMonth": 5174424, "sharesShortPreviousMonthDate": 1740700800, "dateShortInterest": 1743379200, "sharesPercentSharesOut": 0.0664, "heldPercentInsiders": 0.15463, "heldPercentInstitutions": 0.92904, "shortRatio": 5.43, "shortPercentOfFloat": 0.13270001, "impliedSharesOutstanding": 71811504, "bookValue": 4.73, "priceToBook": 0.27272725, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -165839008, "trailingEps": -2.33, "forwardEps": -3.57, "enterpriseToRevenue": -3.497, "enterpriseToEbitda": 1.267, "52WeekChange": -0.90076923, "SandP52WeekChange": 0.05430484, "quoteType": "EQUITY", "currentPrice": 1.29, "targetHighPrice": 10.0, "targetLowPrice": 2.2, "targetMeanPrice": 5.96667, "targetMedianPrice": 6.0, "recommendationMean": 2.3, "recommendationKey": "buy", "numberOfAnalystOpinions": 9, "totalCash": 371084000, "totalCashPerShare": 5.167, "ebitda": -186168992, "totalDebt": 42649000, "quickRatio": 7.133, "currentRatio": 7.322, "totalRevenue": 67425000, "debtToEquity": 12.649, "revenuePerShare": 0.949, "returnOnAssets": -0.23861, "returnOnEquity": -0.42828, "grossProfits": 67425000, "freeCashflow": -67098248, "operatingCashflow": -170860000, "grossMargins": 1.0, "ebitdaMargins": -2.76113, "operatingMargins": -1.71647, "financialCurrency": "USD", "symbol": "ZNTL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "longName": "Zentalis Pharmaceuticals, Inc.", "exchange": "NGM", "messageBoardId": "finmb_647536411", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 2.3809502, "regularMarketPrice": 1.29, "shortName": "Zentalis Pharmaceuticals, Inc.", "corporateActions": [], "postMarketTime": 1744920598, "regularMarketTime": 1744920001, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1585920600000, "postMarketChangePercent": -2.23256, "postMarketPrice": 1.2612, "postMarketChange": -0.0288, "regularMarketChange": 0.029999971, "regularMarketDayRange": "1.23 - 1.34", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 1567500, "fiftyTwoWeekLowChange": 0.27999997, "fiftyTwoWeekLowChangePercent": 0.2772277, "fiftyTwoWeekRange": "1.01 - 13.46", "fiftyTwoWeekHighChange": -12.17, "fiftyTwoWeekHighChangePercent": -0.9041605, "fiftyTwoWeekChangePercent": -90.07692, "earningsTimestamp": 1743019500, "earningsTimestampStart": 1746448200, "earningsTimestampEnd": 1746793800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.33, "epsForward": -3.57, "epsCurrentYear": -2.25164, "priceEpsCurrentYear": -0.57291573, "fiftyDayAverageChange": -0.5141001, "fiftyDayAverageChangePercent": -0.28496206, "twoHundredDayAverageChange": -1.62745, "twoHundredDayAverageChangePercent": -0.557833, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.3 - Buy", "cryptoTradeable": false, "displayName": "Zentalis Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-04-19"}]